TD Private Client Wealth LLC Sells 945 Shares of United Therapeutics Corporation $UTHR

TD Private Client Wealth LLC reduced its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 21.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,436 shares of the biotechnology company’s stock after selling 945 shares during the period. TD Private Client Wealth LLC’s holdings in United Therapeutics were worth $1,674,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in UTHR. Darwin Global Management Ltd. bought a new position in United Therapeutics during the third quarter worth about $317,617,000. Baillie Gifford & Co. bought a new stake in shares of United Therapeutics in the 4th quarter valued at approximately $157,390,000. UBS Group AG raised its holdings in shares of United Therapeutics by 45.3% in the 4th quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after buying an additional 70,445 shares in the last quarter. Soleus Capital Management L.P. lifted its position in shares of United Therapeutics by 35.0% during the 2nd quarter. Soleus Capital Management L.P. now owns 209,794 shares of the biotechnology company’s stock worth $60,284,000 after buying an additional 54,400 shares during the period. Finally, Legal & General Group Plc lifted its position in shares of United Therapeutics by 0.6% during the 3rd quarter. Legal & General Group Plc now owns 199,656 shares of the biotechnology company’s stock worth $83,698,000 after buying an additional 1,137 shares during the period. Institutional investors own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $586.75, for a total value of $4,870,025.00. Following the completion of the sale, the executive vice president owned 45,172 shares in the company, valued at approximately $26,504,671. This trade represents a 15.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $567.31, for a total transaction of $5,673,100.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $10,708,543.56. This represents a 34.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 550,413 shares of company stock worth $305,867,937 in the last quarter. Insiders own 8.60% of the company’s stock.

United Therapeutics Stock Performance

Shares of UTHR opened at $566.80 on Wednesday. The stock has a fifty day moving average price of $561.48 and a two-hundred day moving average price of $509.54. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35. The company has a market cap of $24.06 billion, a price-to-earnings ratio of 20.92, a PEG ratio of 1.83 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the previous year, the company posted $6.63 EPS. United Therapeutics’s revenue for the quarter was down 1.6% on a year-over-year basis. As a group, research analysts predict that United Therapeutics Corporation will post 27.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on UTHR. HC Wainwright upped their price target on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Morgan Stanley set a $516.00 price objective on United Therapeutics in a report on Thursday, May 7th. TD Cowen boosted their target price on shares of United Therapeutics from $575.00 to $660.00 and gave the company a “buy” rating in a research note on Monday, March 30th. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Cantor Fitzgerald increased their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research report on Thursday, March 12th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.